Peer-Reviewed Journal Details
Mandatory Fields
van der Kamp, I;Draper, LA;Smith, MK;Buttimer, C;Ross, RP;Hill, C
2020
December
Pharmaceuticals
A New Phage Lysin Isolated from the Oral Microbiome Targeting Streptococcus pneumoniae
Validated
WOS: 6 ()
Optional Fields
BACTERIOPHAGE-LYTIC ENZYMES PROTEIN FAMILIES DATABASE TRANSFER-RNA GENES IN-VITRO ANTIBACTERIAL ACTIVITY BACTERICIDAL ACTIVITY OTITIS-MEDIA MOUSE MODEL BIOFILMS BINDING
13
Streptococcus pneumoniae is highly pathogenic and causes several mucosal and invasive infections. Due to the rising number of multidrug-resistant (MDR) strains of S. pneumoniae, new antimicrobials with alternative mechanisms of action are urgently needed. In this study, we identified two new Streptococcal phages from the oral microbiome, 23TH and SA01. Their lysins, 23TH_48 and SA01_53, were recombinantly expressed, characterized and tested for their lethality. SA01_53 was found to only lyse its host strain of S. anginosus, while 23TH_48 was found to possess a broader lytic activity beyond its host strain of S. infantis, with several S. pneumoniae isolates sensitive to its lytic activity. 23TH_48 at a concentration of five activity units per mL (U/mL) was found to reduce cell counts of S. pneumoniae DSM 24048 by 4 log(10) colony forming units per mL (CFU/mL) within 1 h and effectively prevented and destroyed biofilms of S. pneumoniae R6 at concentrations of 228.8 ng/mu L and 14.3 ng/mu L, respectively. Given its high lytic activity, 23TH_48 could prove to be a promising candidate to help combat pneumococcal infections.
BASEL
1424-8247
10.3390/ph13120478
Grant Details